Abstract library

83 results for "burden of illness".
#259 Risk of Cardiovascular Events (CV) in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NETs are malignant neoplasms capable of systemic hormone production. Oversecretion of hormones can result in many different symptoms, including CV events such as CAD, valvular disease and stroke.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Chen C C, Liu Z M, Hess G P, Yao J C, ...
#636 Illness Perceptions, Risk Perception and Worry in Patients with Inherited Paragangliomas
Introduction: Carriers of germline mutations in subunits B and D of the succinate dehydrogenase (SDH) gene are at risk for developing paragangliomas (PGLs). The way a person perceives this risk and worries about it may be influenced by his or her perceptions about PGLs.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: MD Leonie Van Hulsteijn
#1276 Caregivers’ Burden of Patients with Neuroendocrine Tumor and Related Factors
Introduction: Rare and increasing rapidly,patients with NETs have got more and more attention.With so many unknown and the long course of the disease, the caregaviers should bear a long and huge burden.However, the relative reviews are rare.
Conference: 13th Annual ENETS conference (2016)
Category: ...none of the above
Presenting Author: Liyan Zhang
Authors: Zhang L, ...
#109 Transarterial chemoebolization (TACE) of liver metastases derived from neuroendocrine tumors is an effective treatment only in patients with low or mediate hepatic tumor burden
Introduction: The onset of metastases in patients with neuroendocrine tumors of the gastrointestinal tract (GEP-NET) represents a negative predictor of survival and tumor-associated complications. Thereby, most of these patients develop liver metastases during their disease. Transarterial chemoembolization (TACE) has been shown before to be an effective and safe treatment of liver metastases. However, the optimal time point in treatment of liver metastases has not yet been determined, especially in patients with non-functional GEP-NET.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Anja Rinke
Authors: Rinke A, König A, Müller D, König U, ...
#260 Risk of Hepatic and Gastrointestinal (GI) Events in Patients Newly Diagnosed with Neuroendocrine Tumors (NET)
Introduction: NET derives from peptide- and hormone-producing cells scattered throughout the body. In excess, these can lead to many clinical manifestations, including GI events (ex. enteritis, and liver disease).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Chi-Chang Chen
Authors: Hess G P, Liu Z M, Chen C C, Yao J C, ...
#1231 Neuroendocrine Tumor (NET) Patient (pt) Experience and Disease Burden: Results from the First Global NET Pt Survey - A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals
Introduction: Global data on impact of NETs on pts’ lives, including differences by disease location, are poorly described. We present global data on pt experience and disease burden by NET type.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Professor Philippe Ruszniewski
Keywords: Symptom burden
#1857 Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements
Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: MD Amit Tirosh
Keywords: PET burden
#29 Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients
Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#2090 Financial Toxicity in Patients with Neuroendocrine Tumor Disease. A so far Underestimated "Side Effect" of Cancer in Germany?
Introduction: Cancer is not only associated with physical and psychological, but also financial burden. In contrast to other countries, the socio-economic impact of cancer for patients in Germany, with a third party paid health care system, is poorly understood.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Prof.Dr.Dr. Eva Caroline Winkler
#809 Serum Chromogranin A is a Predictor for Liver Metastatic Tumor Burden and Therapeutic Response in Advanced Non-Functional Pancreatic Neuroendocrine Tumors
Introduction: The relationship between CgA level and liver metastatic (LM) tumor burden as well as therapeutic response is not well-established.
Conference: 11th Annual ENETS Conference (2014)
Category: Biomarkers
Presenting Author: M.D. Xu Han
Authors: Zhang C, Han X, Tang M, Ji Y, ...
Keywords: CgA NF-PNETs LM